Search

Contact Us

Author: admin

Published by

Integral Molecular Earns Back-to-Back Top Workplace Honors from The Philadelphia Inquirer

Philadelphia – Integral Molecular, a founding member of Philadelphia’s biotechnology community, has again been named a Top Workplace by The Philadelphia Inquirer. The honor […]

Read More

Published by

The Consequences of Off-Target Binding Are Real. So Are the Solutions.

Off-target binding doesn’t always cause harm—but when it goes undetected, the consequences can be serious. Published case studies document off-target interactions that caused adverse […]

Read More

Published by

1 in 3 Antibody Drug Candidates Bind Off-Targets. Here’s What That Means.

In this article: How common is off-target binding, really? Does polyspecificity persist into late-stage clinical development? Why can’t you predict off-targets from sequence analysis […]

Read More

Published by

Webinar Presented by Integral Molecular and The Antibody Society – 100+ Undruggable Targets Unlocked Through Parallel MAb Engineering

Thursday, June 25, 2026 11 am EDT View the recording Many high value therapeutic targets, particularly multipass membrane proteins, remain untapped due to technical […]

Read More

Published by

How Is the MPA Being Qualified by the FDA?

In 2021, we began working with the FDA to qualify the MPA as a Drug Development Tool through the ISTAND program. While the FDA […]

Read More

Published by

USPTO Allows Antibody Genus Claims in Patent Enabled by Integral Molecular’s Paratope-PLUS™ CDR-Scanning

Data-Driven Technology Re-establishes a Pathway for Antibody Genus Claims that Meet US Patent Requirements Philadelphia – Integral Molecular, the industry leader in the discovery […]

Read More

Published by

Are Tissue Cross-Reactivity Studies Sufficient for Biotherapeutic Specificity Testing?

Even though TCR is widely used and has long been recommended by the FDA, it has a long and much-discussed list of limitations. There […]

Read More

Published by

Integral Molecular Appoints Cheryl Paes as Vice President of Commercial Strategy

Philadelphia – Integral Molecular, the industry leader in the discovery and characterization of antibodies against membrane proteins, announces that Cheryl Paes has joined the […]

Read More

Published by

What Tools Are Available for Specificity Testing During Drug Development?

Even though monoclonal antibodies are prized for their specificity, 1 in 3 lead candidates exhibit off-target binding. Because off-target interactions are so common and their safety consequences so large, we need accurate methods for identifying them. […]

Read More

Search